Phase I/II Study for RV-001

Open-Label, Dose Escalation, Single-dose Study of RV-001 in Subjects with Retinitis Pigmentosa (Phase I/II)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2033240611

Enrollment

Registered

2025-01-15

Start date

2025-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinitis Pigmentosa

Interventions

Administration of investigational product

Eligibility

Inclusion criteria

Inclusion criteria: 18 years old and up at the time of ICF signature Diagnosis of non-syndromic Retinitis Pigmentosa

Exclusion criteria

Exclusion criteria: Diagnosed with an inherited retinal degenerative disease other than non-syndromic Retinitis Pigmentosa or systemic symptoms, such as hearing loss. Prior receipt of any genetic, cell-based or optogenetic therapy for Retinitis Pigmentosa, or prior participation in clinical trials for such therapies.

Design outcomes

Primary

Measure	Time frame
Dose-Limiting Toxicity	—

Contacts

Public ContactYusaku Katada

Restore Vision Inc.

chiken@restore-vis.com+81-90-5068-2405

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026